Zobrazeno 1 - 10
of 184
pro vyhledávání: '"N Subbotina"'
Autor:
T. N. Subbotina, A. A. Shalyova, A. I. Shevchenko, E. A. Pozdysheva, Ya. A. Voytsekhovskaya, K. O. Mironov
Publikováno v:
Онкогематология, Vol 19, Iss 1, Pp 92-98 (2024)
Background. According to WHO guidelines, one of the criteria for diagnosis of polycythemia vera is the presence of somatic mutations in exon 12 of the JAK2 gene, but to date there is no universally accepted simple method to analyze these mutations. W
Externí odkaz:
https://doaj.org/article/3fc284f3fa844d70873a22080ed63bb9
Publikováno v:
Oftalʹmologiâ, Vol 20, Iss 2, Pp 260-265 (2023)
Purpose: to expand and modernize the technology of primary microsurgical treatment of extensive scleral wounds due to simultaneous subtotal vitrectomy, primary treatment of retinal and choroid wounds, filling of tissue defects with autologous conditi
Externí odkaz:
https://doaj.org/article/bc2c6ce65590454387b6f122b5c0ff91
Publikováno v:
Российский офтальмологический журнал, Vol 16, Iss 1, Pp 71-76 (2023)
Purpose: to present the functional results of primary early vitrectomy in patients with subtotal and total hemophthalmos with penetrating wounds and severe contusions of the eye. Material and methods. 41 patients were observed, including 24 patients
Externí odkaz:
https://doaj.org/article/f1ad5c26a9414cbea207935c32219304
Autor:
T. N. Subbotina, I. E. Maslyukova, K. S. Semashchenko, G. A. Khodos, D. V. Kurochkin, A. A. Shalyova, M. A. Mikhalev, E. V. Vasiliev, M. G. Osadchaya, E. A. Dunaeva, A. S. Esman, K. O. Mironov
Publikováno v:
Онкогематология, Vol 18, Iss 1, Pp 63-75 (2023)
Background. The development of myelofibrosis (MF) is driven by complex molecular genetic events that include driver somatic mutations responsible for the constitutive activation of the JAK/STAT signaling pathway (JAK2, CALR, and MPL), additional muta
Externí odkaz:
https://doaj.org/article/271d47d097ae4504ac8bd87fab744cd1
Publikováno v:
Онкогематология, Vol 17, Iss 4, Pp 118-125 (2022)
Background. The presence of the FLT3-ITD mutations in patients with AML serves as a marker of poor prognosis, which is included in the ELN 2017 risk stratification guideline. The main criterion for dividing patients into groups according to the predi
Externí odkaz:
https://doaj.org/article/949671ee51664c06bc72c94200295a60
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 18, Iss 3, Pp 289-296 (2022)
Aim. To study the association of nucleotide polymorphisms in platelet receptor and cytochrome P450 genes with the development of resistance to antiplatelet drugs in CHD patients.Material and Methods. The study included 243 patients diagnosed with CHD
Externí odkaz:
https://doaj.org/article/fd842221fda9496592f4ed26bc272272
Autor:
T. N. Subbotina, I. E. Maslyukova, D. V. Kurochkin, M. A. Mikhalev, M. G. Osadchaya, V. A. Khorzhevskiy, T. A. Garkusha, E. A. Dunaeva, K. O. Mironov
Publikováno v:
Онкогематология, Vol 17, Iss 2, Pp 30-35 (2022)
JAK2 mutations can be associated with any phenotypic form of chronic myeloproliferative neoplasia, while MPL and CALR mutations occur, as a rule, in cases of essential thrombocythemia and primary myelofibrosis and they are not observed in polycythemi
Externí odkaz:
https://doaj.org/article/47182056f2d748148f454fefc5457c9c
Autor:
T. N. Subbotina, D. V. Kurochkin, I. E. Maslyukova, A. S. Khazieva, E. V. Vasiliev, M. A. Mikhalev, E. A. Dunaeva, K. O. Mironov
Publikováno v:
Онкогематология, Vol 16, Iss 2, Pp 48-55 (2021)
Background. In accordance with the World health organization clinical guidelines, the analysis of somatic mutations in the CALR gene, as well as mutations in the JAK2 and MPL genes, are included in the list of criteria for the Ph-myeloproliferative n
Externí odkaz:
https://doaj.org/article/43c934e311f744ed94dab242733f6db9
Autor:
T. N. Subbotina, I. E. Maslyukova, A. A. Faleeva, P. A. Nikolaeva, A. S. Khazieva, E. A. Dunaeva, K. O. Mironov, L. B. Polushkina, I. S. Martynkevich, S. V. Vereshchagina, B. V. Barankin
Publikováno v:
Онкогематология, Vol 15, Iss 2, Pp 85-91 (2020)
Background. There are problems related to both quantitative assessment of an allele burden level of a mutant gene and interpretation of results in DNA samples with the burden level of the mutant allele less than 15–20 %, when using Sanger sequencin
Externí odkaz:
https://doaj.org/article/bc3b0376a2864fffaa914ecdf25e92fa
Autor:
Andrei S. Levashov, Svetlana R. Zagidullina, Anna M. Stroganova, Dmitrii A. Khochenkov, Marina V. Ryzhova, Sergei K. Gorelyshev, Shavkat U. Kadirov, Stepan S. Babelyan, Vasilii A. Grigorenko, Dmitrii A. Sidel’nikov, Natalia N. Subbotina, Vidmante V. Daylidite, Georgii L. Mentkevich
Publikováno v:
Современная онкология, Vol 22, Iss 1, Pp 66-76 (2020)
Background. During the past 20 years, some large international studies have been conducted that evaluated the effectiveness of treatment programs for children with medulloblastoma. At the same time, in the standard risk group, fairly high rates of 5-
Externí odkaz:
https://doaj.org/article/a12eb34ca0b74cc593911e1f8ebacdcb